The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists. - Test2 - elhamkhani - TriplyDB

The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists.

The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists.

http://www.wikidata.org/entity/Q37889252

about

Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology Long-acting versus standard non-ergot dopamine agonists in Parkinson's disease: a meta-analysis of randomized controlled trials.Effect of bromocriptine alginate nanocomposite (BANC) on a transgenic Drosophila model of Parkinson's disease.Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.Safinamide for the treatment of Parkinson's disease.Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies.Pergolide block of the cloned Kv1.5 potassium channels.

P2860

Q26738349-3C5246B6-DDB6-4932-810B-B3673AE4EC66 Q35109436-77D79BD0-A44B-4CAF-82CA-25002E02C247 Q36506605-4CD950CC-05CC-4CD2-9377-775475E3302C Q38112589-11E0DEB8-2172-45F6-8278-85FF5A071237 Q38258514-A7FCB742-33D7-4CDB-A494-10071FB335B2 Q38639264-EF47900A-720E-493C-8EC1-596549BF6C6D Q43710067-B609B0D9-D156-438A-B82C-7EA4B84BFC20

P2860

The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists.

http://www.wikidata.org/entity/Q37889252

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The risk of valvular regurgita ...... th dopamine receptor agonists.

@en

The risk of valvular regurgita ...... th dopamine receptor agonists.

@nl

type

label

The risk of valvular regurgita ...... th dopamine receptor agonists.

@en

The risk of valvular regurgita ...... th dopamine receptor agonists.

@nl

prefLabel

The risk of valvular regurgita ...... th dopamine receptor agonists.

@en

The risk of valvular regurgita ...... th dopamine receptor agonists.

@nl

P1433

Q37889252-0714F64B-AD74-416E-866B-77F2042955EA

P1476

Q37889252-9A9A3DC5-B33B-4484-8C45-25283318D67F

P2093

Q37889252-150AC773-3D8B-41F3-B77F-6ECA395179FF

Q37889252-189DE3AB-7FDA-40AC-A61C-8ECEF5F34A0C

Q37889252-50E05953-6B62-4BA9-B5C4-D2ED452D19FC

Q37889252-CDA8D257-FF30-47BE-9EBA-1B95E8810E04

P2860

Q37889252-0370F86F-D7B6-498C-8588-A7A91C66F346

Q37889252-0E881138-482E-4C4C-8045-FD63692512C4

Q37889252-19E0FEFC-CBDA-434F-9DFE-ADBAD169FAD2

Q37889252-1D29A4A2-3F20-4B94-B8B1-403E17B1983D

Q37889252-21E3A4A8-67CC-4EAC-BD47-6DDD5391378B

Q37889252-2F9241D4-D964-4CFD-98D7-BCCB26C09F5D

Q37889252-333AB67E-8357-4D00-8336-5B5122933E3C

Q37889252-41091990-5482-496B-BC77-4FD3877C0DCB

Q37889252-446B67C7-7E7D-4B4C-BBA5-1351A441D74C

Q37889252-47F7A545-D57B-41C1-AF28-F7ACB98ED41F

P304

Q37889252-187C38A9-76AB-471F-929D-198926C03070

P31

Q37889252-6A2F4C53-6AA5-48A8-B6E5-CDCFCE2A0B6A

Q37889252-92c3ef5f-668a-4b46-96a3-5cc6c190e809

P356

Q37889252-F785172C-2B9F-4A5D-AC4D-2274BA9F22D5

P407

Q37889252-EF6719A4-4050-4398-9891-81536131BEA1

P433

Q37889252-ECD23D92-AC6C-469F-BC54-3707E6E1E773

P478

Q37889252-8406BD57-7A4D-4387-9022-2CFDAFCE7690

P577

Q37889252-37C79FFB-56FB-4905-9E9A-454412F8F666

P698

Q37889252-971AECDD-EEA2-483E-BD56-C370C44C739F

P921

Q37889252-7E16BB57-81F7-40C1-9521-FD6F846B1EEB

Q37889252-fbcd661f-7374-48ed-82a7-45a7cf89f354

P356

P1433

Movement Disorders

P1476

The risk of valvular regurgita ...... th dopamine receptor agonists.

@en

P2093

Erik Dupont

http://www.w3.org/2001/XMLSchema#string

Karen Østergaard

http://www.w3.org/2001/XMLSchema#string

Steen Hvitfeldt Poulsen

http://www.w3.org/2001/XMLSchema#string

Vibeke Guldbrand Rasmussen

http://www.w3.org/2001/XMLSchema#string

P2860

Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes

Valvular heart disease associated with fenfluramine-phentermine

Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis

Valvular heart disease and the use of dopamine agonists for Parkinson's disease

Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.

P304

801-806

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.23470

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21671508

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease